LCM
CYT

Laurion Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Laurion Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-316,201
Closed -$961K – 659
2023
Q4 		$961K Sell
316,201
-43,299
-12% -$131K 0.01% 345
2023
Q3 		$1.02M Hold
359,500
– – 0.01% 366
2023
Q2 		$935K Hold
359,500
– – 0.01% 374
2023
Q1 		$654K Hold
359,500
– – ﹤0.01% 319
2022
Q4 		$593K Hold
359,500
– – ﹤0.01% 348
2022
Q3 		$690K Hold
359,500
– – ﹤0.01% 385
2022
Q2 		$1.07M Buy
+359,500
New +$918K 0.02% 274

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.65B AUM 18.1% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Laurion Capital Management's CYT Position: Q1 2024 in Review

Laurion Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 316,201 shares — an estimated $961K sold.

Laurion Capital Management first reported a position in CYT in Q2 2022 and held it in 7 quarters. The position peaked at $1.07M in Q2 2022. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Laurion Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Laurion Capital Management sold 316,201 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $961K.
  • Laurion Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
  • Laurion Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.07M in Q2 2022.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.